SCHEMBL19355264

SCHEMBL19355264

c1cnc2cc(-c3cc(NCCc4ccnc5c4OCCO5)ncn3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.42
CLK4 Q9HAZ1 14/20 0.39
CYP1A2 P05177 11/20 0.39
CYP3A4 P08684 11/20 0.39
ALDH1A1 P00352 9/20 0.39
CYP2D6 P10635 9/20 0.39
HSD17B10 Q99714 8/20 0.39
CYP2C19 P33261 6/20 0.39
ALOX15 P16050 6/20 0.39
DYRK1A Q13627 4/20 0.39
CYP2C9 P11712 3/20 0.39
TP53 P04637 2/20 0.39
MAPK1 P28482 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
CLK1 P49759 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
USP2 O75604 6/20 0.38
MEN1 O00255 6/20 0.38
KMT2A Q03164 6/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19355404 0.93 CLK4 (0.39) TRPV1CLK4CYP1A2CYP3A4ALDH1A1
SCHEMBL19355116 0.84 CLK4 (0.38) CLK4CYP1A2CYP3A4ALDH1A1CYP2D6
SCHEMBL19355263 0.83 CLK4 (0.41) CLK4CYP1A2CYP3A4ALDH1A1CYP2D6
SCHEMBL22838684 0.82 CYP1A2 (0.43) CLK4CYP1A2CYP3A4ALDH1A1CYP2D6
SCHEMBL19355123 0.81 CYP1A2 (0.38) TRPV1CLK4CYP1A2CYP3A4ALDH1A1
SCHEMBL17634599 0.81 TRPV1 (0.40) TRPV1CLK4CYP1A2CYP3A4ALDH1A1
SCHEMBL19355393 0.80 CLK4 (0.37) TRPV1CLK4CYP1A2CYP3A4ALDH1A1
SCHEMBL20842643 0.80 ALDH1A1 (0.34) TRPV1CLK4CYP1A2CYP3A4ALDH1A1
SCHEMBL19905243 0.80 TRPV1 (0.39) TRPV1CLK4CYP1A2CYP3A4ALDH1A1
SCHEMBL22838651 0.79 TRPV1 (0.41) TRPV1CLK4CYP1A2CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193341-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2018-07-12 US disclosed
US-20170258789-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258789-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK TRPV1 4231/4885CLK4 383/4885CYP1A2 2215/4885
US-20180193341-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK TRPV1 4231/4885CLK4 383/4885CYP1A2 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.